Real-world observational study of somatostatin analogues and rescue medication use for neuroendocrine tumors in Canada

#3815

Introduction: Both octreotide long-acting release (OCT-LAR) and lanreotide autogel (LAN-ATG) are available in Canada for the management of neuroendocrine tumors (NETs). Patients can switch between SSAs due to effectiveness, adverse events (AEs), preference or reimbursement. For patients with functional disease, short acting SSAs can be used concomitantly as rescue medication to improve symptom control.

Aim(s): This study investigated the association between switching SSAs and rescue medication use in a real-world setting in Canada.

Materials and methods: Claims data were extracted from the IQVIA’s Canadian Private Drug Plan, Ontario Drug Benefit program, and Régie de l’assurance maladie du Québec databases. Eligible NET patients were those with a first SSA prescription dispensed between Sept 1, 2005 and Dec 31, 2021 and who switched SSAs. Wilcoxon signed ranked test was used to compare rescue medication usage pre- and post-switch.

Conference:

Presenting Author:

Authors: Rayson D, Troesch M, Laforty C, Badin M, Liovas A,

Keywords: Neuroendocrine tumor, Somatostatin analogues, Lanreotide, Octreotide, SSA switch,